Glepaglutide: Molecular Structure

Molecular Structure#

Glepaglutide (ZP1848) is a rationally designed synthetic analog of human glucagon-like peptide-2 (GLP-2) that overcomes the pharmacological limitations of the native hormone while enabling a novel ready-to-use liquid formulation. The design was published in the Journal of Medicinal Chemistry (PMID: 39851172), detailing how each modification contributes to the clinical profile.

Design Principles#

Native human GLP-2 is a 33-amino acid peptide that is:

1. Rapidly degraded by DPP-IV (half-life ~7 minutes)
2. Chemically unstable in aqueous solution (prone to oxidation and deamidation)
3. Physically unstable (tendency to aggregate and fibrillate)

Glepaglutide addresses all three limitations through:

1. Nine amino acid substitutions: Confer resistance to DPP-IV cleavage, reduce chemical degradation (oxidation, deamidation), and improve physical stability
2. C-terminal hexalysine tail (SIP technology): The Structure Inducing Probe (SIP) technology adds six lysine residues at the C-terminus. This improves aqueous solubility and stability, enabling the ready-to-use liquid formulation, and also significantly improves synthetic yields
3. No lipid modifications or disulfide bonds: Unlike many other long-acting peptide analogs (e.g., semaglutide with fatty acid chain, teduglutide with single-point mutation), glepaglutide achieves its extended action through a depot mechanism rather than albumin binding

Chemical Properties#

Pharmacokinetics#

Glepaglutide exhibits unusual pharmacokinetics dominated by depot formation and metabolite activity:

Subcutaneous Depot Mechanism#

Following subcutaneous injection, glepaglutide forms a depot at the injection site. Two main metabolites are generated by C-terminal proteolytic cleavage:

• M1: 35-amino acid metabolite (loss of 4 C-terminal lysines)
• M2: 34-amino acid metabolite (loss of 5 C-terminal lysines)

Both M1 and M2 retain full GLP-2 receptor potency comparable to the parent compound. The slow release of these metabolites from the subcutaneous depot drives the extended pharmacological action.

Key PK Parameters#

Pharmacodynamics#

The pharmacodynamic effects of glepaglutide include:

• Increased villus height and crypt depth (documented by histomorphometry)
• Increased intestinal blood flow (documented by CT angiography)
• Reduced fecal wet weight output
• Improved fluid and energy absorption
• Effects build over weeks to months as intestinal adaptation progresses

Comparison with Other GLP-2 Analogs#

Stability#

Glepaglutide's defining structural advantage is its stability in aqueous solution. This is achieved without lipid modifications or chemical linkers, relying instead on the amino acid substitutions and SIP tail to prevent:

• Oxidation of methionine and tryptophan residues
• Deamidation of asparagine and glutamine residues
• Aggregation and fibrillation

This stability enables the ready-to-use autoinjector formulation, eliminating the reconstitution step required for teduglutide and reducing administration complexity for patients who may inject multiple times per week.

Related Reading#

• Glepaglutide overview and research guide
• Peptides similar to Glepaglutide
• Glepaglutide research evidence